N/A
Completed N=34,100
Transatlantic Active Surveillance on Cardiovascular Safety of NuvaRing (TASC)
Source: ClinicalTrials.gov NCT00524771 ↗Enrolled (actual)
34,100
Serious AEs
3.9%
Results posted
Apr 2014
Primary outcomePrimary: Number of Participants With Venous Thromboembolism (VTE) — 19; 26; 21 participants
Summary
The objective of this study is to characterize and compare the risks of short- and long-term use of NuvaRing® with marketed combined oral contraceptives.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Venous Thromboembolism (VTE) |
19; 26; 21 | — |
| PRIMARY Number of Participants With Arterial Thromboembolism (ATE) |
5; 8; 6 | — |
Eligibility Criteria
Inclusion Criteria
- women who are prescribed NuvaRing® or a combined oral contraceptive and who are new users (Starters, restarters or switchers) of the formulation
Exclusion Criteria
- women who do not consent to participate in the study
Data sourced from ClinicalTrials.gov (NCT00524771). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.